DGAP-News: Eckert & Ziegler Classified in California as Essential Business


 

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous/Statement
Eckert & Ziegler Classified in California as Essential Business

22.03.2020 / 17:25
The issuer is solely responsible for the content of this announcement.


Berlin, 22 March 2020. The production sites in California of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX), in fiscal year 2019 responsible for more than one third of the groups revenue, will not be affected by "Safer at Home" orders for non-critical Manufacturing entities that went into effect in response to the COVID-19 pandemic there Friday evening Pacific Time. As is the case with Eckert & Ziegler's European plants, most products manufactured in California are categorized as being part of the health systems or of essential infrastructure. Therefore, the sites are exempt from governmental closing orders. This also applies to the production site in New York.

In other locations and the European Union, where the remainders of Eckert & Ziegler's production sites are located, so far no closing orders have been issued. In the opinion of the Management Board, however, the situation in almost all places is similar to California, not only for the live saving cancer treatment devices or radiopharmaceuticals that are manufactured in these other locations, but also for services and industrial products. Cobalt irradiation sources, seemingly just a technical component, are for example needed for the gamma sterilization of medical devices and lately see a soaring demand.

"The group's economic performance will nevertheless be affected by the global governmental reactions to the corona crisis" cautions the CEO of the group, Dr. Andreas Eckert. "The turmoil caused by social thinning-out measures, curfews, school closures, or travel restrictions has already led to the delay or cancellation of orders and increased cost. Furthermore, the widespread paralyzation of public institutions and the interruptions of well-established routines may influence the ability to implement countermeasures swiftly."

The group will provide further details on the 2020 outlook together with the details of the 2019 annual report on 31 March 2020.

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com



22.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1003703

 
End of News DGAP News Service

1003703  22.03.2020 

fncls.ssp?fn=show_t_gif&application_id=1003703&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 138,63 168,71 178,49 176,14 180,44 222,26 246,09
EBITDA1,2 26,62 32,14 43,13 44,64 57,04 55,52 58,83
EBITDA-Marge3 19,20 19,05 24,16 25,34 31,61 24,98
EBIT1,4 17,97 23,39 32,06 33,69 47,45 44,54 45,45
EBIT-Marge5 12,96 13,86 17,96 19,13 26,30 20,04 18,47
Jahresüberschuss1 15,12 16,89 22,48 23,11 34,66 29,75 26,77
Netto-Marge6 10,91 10,01 12,59 13,12 19,21 13,39 10,88
Cashflow1,7 26,83 21,21 40,43 36,79 33,86 34,30 47,40
Ergebnis je Aktie8 0,70 0,78 1,07 1,11 1,66 1,41 1,26
Dividende8 0,20 0,30 0,42 0,45 0,50 0,50 0,17
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

INVESTOR-INFORMATIONEN
©boersengefluester.de
Eckert & Ziegler
WKN Kurs in € Einschätzung Börsenwert in Mio. €
565970 33,680 Halten 713,07
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
21,05 26,02 0,82 37,05
KBV KCV KUV EV/EBITDA
3,22 15,04 2,90 11,60
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,50 0,05 0,15 28.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
14.05.2024 09.08.2024 14.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-16,51% -9,26% -18,45% -22,68%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Eckert & Ziegler Strahlen- und Medizintechnik AG  ISIN: DE0005659700 können Sie bei EQS abrufen


Medtech , 565970 , EUZ , XETR:EUZ